Prelude Therapeutics Incorporated
NASDAQ:PRLDBiotechnology
-$0.14 today
- Market cap
- $191.00M
- Beta
- 1.01
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.94
Volume 0.23M
Average 0.38M
PRLD Total Debt
Short-term and long-term borrowings combined.
Prelude Therapeutics IncorporatedNASDAQ: PRLD
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt broadly unchanged from a year ago
Total debt stood at $17.72M at the end of Q1 FY2026, down 1.1% from a year earlier and down 0.4% from the prior quarter. Over 3 fiscal years it compounded at +113.3% a year.
Context
- Total debt amounted to 14.8% of total assets at the end of Q1 FY2026, up 2.1 pp from a year earlier.
- Total debt increased in 2 of the last 3 fiscal years.
What to watch
Whether total debt keeps falling in the next quarterly balance sheet after a -1.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 17.79M USD
- Year-over-year change
- -1.3%
- 4-year CAGR
- +78.8%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.79M | -1.3% |
| FY2024 | 2024-12-31 | 18.03M | +6.7% |
| FY2023 | 2023-12-31 | 16.89M | +821.8% |
| FY2022 | 2022-12-31 | 1.83M | +5.3% |
| FY2021 | 2021-12-31 | 1.74M | — |
Total Debt vs competitors
How PRLD compares with its peers on the latest reported figures
- Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -1.1% is the 8th highest of 11, against a peer median of +14.9%.
- Total debt amounts to 14.8% of total assets for PRLD, versus a peer median of 18.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.73B USD | +91265.7% | -7.6% | 1.7% | |
| Mar 2026 | $186.62M USD | -13.7% | +96.0% | 59.3% | |
| Dec 2025 | €59.4M EUR | +9.3% | +19.8% | 23.9% | |
| Mar 2026 | $41.99M USD | +20.5% | -7.1% | 18.9% | |
| Mar 2026 | $33.64M USD | +104.5% | -47.8% | 33.4% | |
| Mar 2026 | $26.95M USD | +2.8% | -0.6% | 18.1% | |
| Mar 2026 | $18.26M USD | -8.0% | -0.4% | 28.4% | |
| Mar 2026 | $17.72M USD | -1.1% | +113.3% | 14.8% | |
| Mar 2026 | $10.12M USD | -21.6% | -10.5% | 7.5% | |
| Mar 2026 | $2.33M USD | +190.6% | -50.4% | 2.3% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $2.01M USD | +3715.1% | -76.7% | 1.4% |
| Peer median (excluding PRLD) | — | +14.9% | -7.3% | 18.5% | |
Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 31.83M | 30.61M | 25.29M | 12.47M | 35.26M |
| Short-term Investments | 259.41M | 171.12M | 207.64M | 121.14M | 67.96M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 2.65M | 2.65M | 2.28M | 2.48M |
| Total Current Assets | 295.12M | 204.38M | 235.59M | 135.9M | 105.69M |
| Property, Plant & Equipment (Net) | 5.64M | 6.7M | 37.74M | 35.47M | 32.28M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 4.35M | 9.42M | 4.34M | 4.15M | 3.35M |
| Total Non-current Assets | 9.98M | 16.12M | 42.08M | 39.62M | 35.62M |
| Total Assets | 305.1M | 220.5M | 277.67M | 175.52M | 141.32M |
| Account Payables | 7.84M | 6.78M | 4.58M | 7.73M | 3.98M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 33.73M |
| Other Current Liabilities | 5.01M | 6.21M | 6.61M | 9.79M | 5.4M |
| Total Current Liabilities | 19.2M | 21.7M | 21.83M | 25.64M | 52.99M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 1.8M |
| Other Non-current Liabilities | 0 | 3.36M | 3.34M | 3.09M | 2.84M |
| Total Non-current Liabilities | 0 | 3.36M | 18.75M | 18.42M | 19.68M |
| Total Liabilities | 19.2M | 25.06M | 40.58M | 44.06M | 72.68M |
| Common Stock | 5K | 5K | 5K | 5K | 5K |
| Retained Earnings | (219.12M) | (334.56M) | (456.39M) | (583.56M) | (683.06M) |
| Accumulated OCI | (711K) | (1.69M) | 223K | 35K | 8K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 285.9M | 195.44M | 237.09M | 131.46M | 68.64M |
| Total Debt | 1.74M | 1.83M | 16.89M | 18.03M | 17.79M |
| Net Debt | (30.09M) | (28.77M) | (8.4M) | 5.55M | (17.47M) |
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Intrinsic Alpha fair value
Locked
Current Price
$3.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.